Palisades Therapeutics Unveils Breakthrough Multi-Mechanistic Data for PT150 and PT157 in Resistant Cancers

Dual AR/GR Antagonism, Metabolic Reprogramming, and Lysosomal Bypass Position PT150 and PT157 as Best-in-Class Oncology Candidates

CLIFFSIDE PARK, NJ, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- Pop Test Oncology LLC dba Palisades Therapeutics, a clinical-stage biopharmaceutical company, today released compelling preclinical data for clinical-stage PT150 and its early-stage dimer PT157, demonstrating their superiority over existing glucocorticoid receptor (GR) antagonists like Relacorilant™.

These findings position PT150 and PT157 as transformative therapies for taxane-resistant and AR/GR-driven cancers, including pancreatic, ovarian, liver, prostate, and colorectal malignancies.

Breakthrough Mechanistic Insights

• Dual AR/GR Targeting: Disrupts survival pathways in AR+/GR+ tumors (~30% of pancreatic, ovarian, and prostate cancers).

• Epigenetic Modulation: Reverses PARP resistance (H2AFV↑) induces synthetic lethality in ARID1A-mutant tumors (SMARCA4↓).

• Metabolic & Stromal Targeting: ACADL↓ disrupts fatty acid oxidation; ACTA2↓ reduces fibrosis for improved drug delivery.

• Lysosomal Resistance Bypass: RAB9A↓ prevents taxane sequestration, enhancing chemotherapy efficacy.

• ZTX^® PREDICT Platform Validation: Rapid 5-day in vivo testing identifies responders/non-responders, with high prediction of patient treatment outcome, accelerating preclinical-to-clinical translation.

Strategic Next Steps

• Global Partnerships: Leverage data for potential collaborations with leading companies such as Pfizer, Gilead, Bristol-Myers Squibb, and Astellas.

Why This Matters: PT150 and PT157’s multi-target approach offers hope for durable remissions in resistant pancreatic, ovarian, liver, and prostate cancers.

About Palisades Therapeutics
Palisades Therapeutics is a lean, innovation-driven biotech leveraging a global network of 75+ experts to accelerate transformative oncology therapies. Learn more at www.palisadestherapeutics.com

Disclaimer:
Relacorilant™ is a trademark and drug owned by Corcept Therapeutics. Palisades Therapeutics and its affiliates have no relationship, affiliation, or endorsement from Corcept Therapeutics. Any comparative data regarding Relacorilant™ referenced in this press release, prepared through Perplexity. ai were determined through publicly available publications and are not based on direct collaboration or proprietary information from Corcept Therapeutics.

Forward-looking statements: This release contains projections based on preclinical data. Clinical outcomes may differ.

#Pfizer, #Gilead, #BMS, #Astellas, #Oncology, #CancerResearch

Randi Altschul
Pop Test Oncology/Palisades Therapeutics
+1 201-943-3770
email us here
Visit us on social media:
LinkedIn